Article
Urology & Nephrology
K. Stinesen Kollberg, E. Holmberg, A. Josefsson, J. Hugosson, R. Arnsrud Godtman
Summary: The aim of this study was to describe the level of pre-testing and contamination in the Goteborg-1 prostate cancer screening trial. The results showed that similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Organized screening was found to be more effective in reducing prostate cancer mortality than non-organized testing.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Patrick-Julien Treacy, Ugo G. Falagario, Francois Magniez, Parita Ratnani, Ethan Wajswol, Alberto Martini, Ivan Jambor, Peter Wiklund, Imad Bentellis, Flora Barthe, Natasha Kyprianou, Matthieu Durand, Daniel Steffens, Sascha Karunaratne, Scott Leslie, Ruban Thanigasalam, Ash Tewari
Summary: This study aimed to evaluate the genomic risk of patients with persistent prostate specific antigen (PSA) using mRNA expression analysis and a validated prognostic genomic-risk classifier. The findings revealed unique genomic features of patients with persistent PSA and confirmed that this condition is associated with a worse prognosis.
MINERVA UROLOGY AND NEPHROLOGY
(2023)
Article
Urology & Nephrology
Furkan Dursun, Chen-Pin Wang, Daniel MacCarthy, Ahmed M. Mansour, Deepak K. Pruthi, Dharam Kaushik, Ian M. Thompson, Michael A. Liss
Summary: The purpose of this study was to determine if the absolute PSA value after 6 months of ADT is predictive of survival in patients with prostate adenocarcinoma. The results showed that patients with high and intermediate PSA values had a higher risk of PCSM and all-cause mortality compared to those with low PSA values. This measure can be used to rapidly assess the efficacy of new interventions in clinical trials.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Sebastiaan Remmers, Chris H. Bangma, Rebecka A. Godtman, Sigrid. Carlsson, Anssi Auvinen, Teuvo L. J. Tammela, Louis J. Denis, Vera Nelen, Arnauld Villers, Xavier Rebillard, Maciej Kwiatkowski, Franz Recker, Stephen Wyler, Marco Zappa, Donella Puliti, Giuseppe Gorini, Alvaro Paez, Marcos Lujan, Daan Nieboer, Fritz H. Schroeder, Monique J. Roobol
Summary: Based on the guidelines of the European Association of Urology, a risk-based strategy for prostate cancer screening should be determined by the first prostate-specific antigen (PSA) level and age. In this study, the baseline PSA level was found to guide decisions on the repeat screening interval and had an impact on prostate cancer detection and specific mortality rates.
Article
Andrology
Jeong Hoon Oh, Ho Seok Chung, Myung Soo Kim, Eu Chang Hwang, Seung Il Jung, Dongdeuk Kwon, Kwangsung Park
Summary: PSA parameters have a similar diagnostic value in predicting prostate cancer in men with gray-zone PSA levels regardless of testosterone levels.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2022)
Article
Urology & Nephrology
Ivo I. de Vos, Annick Meertens, Renee Hogenhout, Sebastiaan Remmers, Monique J. Roobol
Summary: This study concludes that PSA-based screening for prostate cancer can reduce metastasis and mortality. The longer the follow-up, the greater the reduction in deaths and metastasis. The study also suggests that starting screening between the ages of 70 and 74 is not effective and repeated screenings are necessary.
Article
Urology & Nephrology
Kendrick Yim, Chaoran Ma, Sigrid Carlsson, Hans Lilja, Lorelei Mucci, Kathryn Penney, Adam S. Kibel, Scott Eggener, Mark A. Preston
Summary: Adding percent free PSA to total PSA improved prediction of clinically significant prostate cancer and fatal prostate cancer. Free PSA can be used to stratify risk in screening and reduce unnecessary prostate biopsies.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Neal Andruska, Benjamin W. Fischer-Valuck, Michael Waters, Elizabeth Juarez Diaz, Temitope Agabalogun, Eric H. Kim, Zachary L. Smith, Randall J. Brenneman, Hiram A. Gay, Gerald L. Andriole, Jeff M. Michalski, Brian C. Baumann
Summary: This study showed that men with higher LN risk scores and Gleason grade benefited from WPRT. WPRT correlated with improved overall survival in men with Gleason 9 and 10 disease or risk of LN involvement >= 10%.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Tarik Benidir, Ethan Austhof, Ryan D. D. Ward, Justin Ream, Jenifer Bullen, Baris Turkbey, Peter A. A. Pinto, Francesco Giganti, Eric A. A. Klein, Andrei S. S. Purysko
Summary: The study aimed to evaluate the impact of UroLift on prostate magnetic resonance imaging (MRI) quality. The results showed that UroLift has a negative impact on MRI quality, particularly in the mid-basal region, obscuring a significant portion of the prostate on diffusion-weighted images.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Vishesh Agrawal, Xiaoyue Ma, Jim C. Hu, Christopher E. Barbieri, Himanshu Nagar
Summary: The optimal treatment for intermediate risk prostate cancer remains unclear. National Comprehensive Cancer Network (NCCN) guidelines suggest active surveillance, prostatectomy, or radiotherapy. This study analyzed U.S. national trends in active surveillance for men with intermediate risk prostate cancer, finding an increasing use of active surveillance with clinical and socioeconomic disparities.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Michael S. Leapman, Kimberly Stone, Roxanne Wadia, Lesley S. Park, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Maria Rodriguez-Barradas, Fatma Shebl, Amy C. Justice, Sheldon T. Brown, Kristina Crothers, Keith M. Sigel
Summary: The risk of prostate cancer among individuals living with human immunodeficiency virus (HIV) is not well understood. This study found that when accounting for less prostate-specific antigen (PSA) testing among HIV-positive individuals, the incidence of prostate cancer was similar to that of HIV-negative individuals.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Maha Hussain, Cora N. Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Ugo De Giorgi, Neal D. Shore, Fred Saad
Summary: This study analyzed the relationship between depth of PSA decline and clinical outcomes in men with nonmetastatic castration-resistant prostate cancer. The results showed that greater depth of PSA decline was associated with improved metastasis-free survival and overall survival, suggesting a previously underestimated relationship between changes in PSA levels and clinical outcomes.
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Nancy N. Wang, Steve R. Zhou, Leo Chen, Robert Tibshirani, Richard E. Fan, Pejman Ghanouni, Alan E. Thong, Katherine J. To'o, Kamyar Ghabili, Jeffrey W. Nix, Jennifer B. Gordetsky, Preston Sprenkle, Soroush Rais-Bahrami, Geoffrey A. Sonn
Summary: The study aimed to develop and validate a nomogram combining PIRADS scores and clinical data to predict the probability of prostate cancer detection in men. Results showed that the nomogram, named SPCC, provided stronger predictive accuracy than using PSA density or PIRADS alone, with robust AUC values in external validation.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Urology & Nephrology
Alan L. Xue, Arveen A. Kalapara, Zita E. Ballok, Sidney M. Levy, Dinesh Sivaratnam, Andrew Ryan, Shakher Ramdave, Richard O'Sullivan, Daniel Moon, Jeremy P. Grummet, Mark Frydenberg
Summary: This study found that the use of Ga-68-PSMA PET/CT and SUVmax may improve the accuracy of risk stratification for patients with intermediate-risk prostate cancer.
JOURNAL OF UROLOGY
(2022)
Article
Multidisciplinary Sciences
Libin Nan, Kai Guo, Mingmin Li, Qi Wu, Shaojun Huo
Summary: A nomogram prediction model for prostate cancer was developed using clinical data, and compared with other prediction models. The results showed that the model had higher predictive value, and could be used to assess the probability of prostate cancer and guide prostate biopsy.
Article
Urology & Nephrology
Gregor Miller, Donna P. Ankerst, Michael W. Kattan, Norbert Hueser, Serge Vogelaar, Ineke Tieken, Uwe Heemann, Volker Assfalg
Summary: A risk tool for predicting kidney transplant outcomes in Europe has been developed based on recipient and donor characteristics, with a 10-year AUC value of up to 0.81. The tool can be accessed at https://riskcalc.org/ktop/ for pre- and post-donor identification predictions.
Article
Urology & Nephrology
William Gondoputro, James Thompson, Melanie Evans, Damien Bolton, Mark Frydenberg, Declan G. Murphy, Anne-Maree Haynes, Shikha Agrawal, Phillip Stricker, Nathan Papa
Summary: The study found that age has an impact on postoperative urinary continence after robot-assisted radical prostatectomy. Urinary bother and pad-usage increase with age, but older patients experience less significant bother despite higher pad-usage.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Gideon Ptasznik, Nathan Papa, Brian D. Kelly, James Thompson, Phillip Stricker, Matthew J. Roberts, Michael S. Hofman, James Buteau, Declan G. Murphy, Louise Emmett, Daniel Moon
Article
Health Care Sciences & Services
Jacob A. Kurowski, Jean-Paul Achkar, David Sugano, Alex Milinovich, Xinge Ji, Janine Bauman, Keyonna R. Griffin, Michael W. Kattan
Summary: This study utilizes natural language processing to develop a computable phenotype health state model for Crohn's disease (CD) and analyzes the transition time between different health states and the effectiveness of treatments. The application of this model can provide a better understanding of the progression of chronic diseases and long-term cost-effectiveness analyses for new therapies.
MEDICAL DECISION MAKING
(2022)
Review
Urology & Nephrology
Sean Ong, Kenneth Chen, Jeremy Grummet, John Yaxley, Matthijs J. Scheltema, Phillip Stricker, Kae Jack Tay, Nathan Lawrentschuk
Summary: This article provides a summary and discussion of international guidelines, position statements, and consensus statements on focal therapy for prostate cancer. The lack of long-term randomized data for focal therapy is highlighted, and the need for high-quality clinical trials with robust outcomes is emphasized. The current consensus and position statements are heterogeneous, indicating a need for globally accepted guidelines for focal therapy planning and follow-up.
Article
Endocrinology & Metabolism
Anira Iqbal, Zehra Tekin, Michael W. Kattan, Xinge Ji, Alex Milinovich, Kevin M. Pantalone, Robert S. Zimmerman, Mina K. Chung, Sangeeta Kashyap
Summary: Initiation of metformin as a first line monotherapy for T2D is not associated with a decreased risk of developing AF.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
(2022)
Article
Pathology
Oliver Best, Ashan Canagasingham, Zhixin Liu, Paul Doan, Anne-Maree Haynes, Warick Delprado, Fiona Maclean, Carlo Yuen, Phillip Stricker, James Thompson
Summary: The pathological grade of prostate cancer is the strongest predictor of recurrence. This study aims to determine whether the composite or index grade group is a better predictor of biochemical recurrence (BCR) in prostate cancer patients who underwent radical prostatectomy. The results showed that patients with a higher index grade group had a higher risk of BCR. Therefore, the index grade group should be used for post-operative counseling regarding prognosis and follow-up.
Article
Oncology
Bhavneet Bhinder, Alison Ferguson, Michael Sigouros, Manik Uppal, Ahmed G. Elsaeed, Rohan Bareja, Hussein Alnajar, Kenneth Wha Eng, Vincenza Conteduca, Andrea Sboner, Juan Miguel Mosquera, Olivier Elemento, Himisha Beltran
Summary: This study analyzed the RNA-sequencing and whole-exome sequencing data of 170 patients with neuroendocrine prostate cancer (NEPC). It found that NEPC has a unique tumor immune landscape compared to other prostate cancer types and small-cell lung cancer (SCLC). NEPC is characterized by a relatively immune-depleted tumor immune microenvironment and less mutations, but has comparable expression of checkpoint genes PD-L1 and CTLA-4 with SCLC. These findings can inform the development of immunotherapy strategies for NEPC.
CLINICAL CANCER RESEARCH
(2023)
Article
Endocrinology & Metabolism
Kevin M. Pantalone, Xinge Ji, Sheldon X. Kong, Jay C. Elliott, Alex Milinovich, Anita D. Misra-Hebert, Ryan Farej, Rakesh Singh, Janine M. Bauman, Robert S. Zimmerman, Tushar J. Vachharajani, Jamie Partridge, Jennifer Cameron, Todd Williamson, Michael W. Kattan
Summary: This brief report uses EHR data to summarize unmet needs in patients with type 2 diabetes and chronic kidney disease and identifies opportunities to optimize management within this patient population.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
(2023)
Editorial Material
Urology & Nephrology
Matthijs J. Scheltema, Athos Katelaris, Phillip D. Stricker
Summary: Focal ablative therapy is a viable treatment option for radio-recurrent prostate cancer, providing local disease control and reducing salvage-treatment-related complications. Irreversible electroporation shows promise as the standard ablative modality for prostate cancer due to its reliable ablation results, electricity-based effect, and acceptable adverse effect profile.
NATURE REVIEWS UROLOGY
(2023)
Editorial Material
Critical Care Medicine
Yuxuan Jin, Michael W. Kattan
Summary: This article identifies common methodological concerns in developing and evaluating statistical prediction models, and provides suggestions to address them.
Article
Urology & Nephrology
Deepak K. Pruthi, Gregor Miller, Donna P. Ankerst, Matthias Neumair, Umberto Capitanio, Andres F. Correa, Brian R. Lane, Eduard Roussel, Thomas B. Mcgregor, Ithaar H. Derweesh, Mauricio Cordeiro, Phillip M. Pierorazio, Carlos Calvo, Hai Bi, Sabrina L. Noyes, Margaret Meagher, Alexander Kutikov, Robert G. Uzzo, Hendrik Van Poppel, Alessandro Larcher, Francesco Montorsi, Michael W. Kattan, Dharam Kaushik, Michael A. Liss
Summary: This study aimed to investigate whether clinical risk factors and morphometric features on preoperative imaging can predict pathological upstaging in cT1 renal cell carcinoma patients. Through a retrospective study, we found that increasing preoperative tumor size, increasing age, diabetes, higher BMI, and male sex were associated with pathological upstaging. Additionally, hilar tumors were more likely to be upstaged.
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Erin M. Mcclure, Geoffrey Sedor, Yuxuan Jin, Michael W. Kattan
Summary: This study investigates the effectiveness of image-guided superficial radiation therapy (IGSRT) compared to Mohs micrographic surgery (MMS) for the treatment of early stage non-melanoma skin cancers (NMSCs). It found that IGSRT-treated NMSCs had a significantly lower 2-year recurrence probability than those treated by MMS, supporting the use of IGSRT as an effective treatment option for individuals with early stage NMSCs.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Meeting Abstract
Oncology
Etsuro Bando, Xinge Ji, Michael W. Kattan, Yusuke Koseki, Kenichiro Furukawa, Keiichi Fujiya, Yutaka Tanizawa, Masanori Terashima
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Anesthesiology
Vladimir Turzhitsky, Lori Bash, Robert Mark, Michael Kattan, Ira Hofer, Richard Urman
ANESTHESIA AND ANALGESIA
(2023)